French pharmaceutical giant Sanofi has announced its biggest acquisition of 2025, agreeing to purchase US biotech company Blueprint Medicines for up to $9.5 billion. This major deal represents the largest healthcare acquisition by a European company this year and marks Sanofi’s continued push into rare disease treatments.
The agreement will see Sanofi pay $129 per share in cash, totaling approximately $9.1 billion upfront. Blueprint shareholders could receive additional payments worth up to $400 million through milestone achievements, bringing the total deal value to $9.5 billion. Blueprint’s stock surged 27% following the announcement, while Sanofi shares dropped about 1%.
Strategic Focus on Rare Blood Disorders
This acquisition centers around Blueprint’s expertise in treating systemic mastocytosis, a rare blood disorder affecting white blood cells. The deal brings Sanofi ownership of Ayvakit, currently the only approved treatment for advanced systemic mastocytosis in both the US and EU markets.
Blueprint expects Ayvakit to generate around $2 billion in annual sales by 2030, making it a valuable addition to Sanofi’s portfolio. The acquisition also includes promising experimental drugs like elenestinib and BLU-808, which could treat various immunology conditions.
Sanofi CEO Paul Hudson described the purchase as a “strategic step forward” in building the company’s rare disease and immunology capabilities. This follows Sanofi’s recent acquisition strategy, including January’s $2.2 billion purchase of Inhibrx and last month’s $470 million deal for Vigil Neuroscience.
The transaction is expected to close in the third quarter of 2025, pending regulatory approval.
This blog post is for information purpose only